Hematological Malignancies

Global Hematological Malignancies Market to Reach US$79.3 Billion by 2030

The global market for Hematological Malignancies estimated at US$55.3 Billion in the year 2024, is expected to reach US$79.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Leukemia, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.2 Billion While China is Forecast to Grow at 5.7% CAGR

The Hematological Malignancies market in the U.S. is estimated at US$15.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.3 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Hematological Malignancies Market - Key Trends & Drivers Summarized

What Are Hematological Malignancies and Why Is Demand for Treatments Rising?

Hematological malignancies, or blood cancers, include conditions such as leukemia, lymphoma, and multiple myeloma, which affect the blood, bone marrow, and lymphatic system. Demand for effective treatments is rising as hematological malignancies represent some of the most complex and challenging cancers to treat, often requiring specialized therapies. With increased understanding of these diseases and improved diagnostic capabilities, healthcare providers are detecting and treating blood cancers earlier, leading to better patient outcomes. As the global cancer incidence rises, particularly in aging populations, the demand for innovative therapies to manage and treat hematological malignancies is intensifying.

How Are Targeted Therapies and Immunotherapies Transforming Treatment?

Targeted therapies and immunotherapies are revolutionizing the treatment of hematological malignancies by providing more precise and effective solutions. Targeted therapies use drugs designed to specifically attack cancer cells while minimizing damage to healthy cells, reducing side effects and improving patient quality of life. Immunotherapies, such as CAR-T cell therapy, harness the immune system to fight cancer, showing significant success in conditions like lymphoma and leukemia. These therapies are particularly valuable for patients who do not respond well to conventional treatments, providing options that improve survival rates and patient outcomes.

What Role Do Clinical Trials and Regulatory Support Play?

Clinical trials are essential for developing and approving new therapies for hematological malignancies, providing valuable data on safety and efficacy. Regulatory agencies, including the FDA and EMA, have granted special designations like “Orphan Drug” and “Breakthrough Therapy” status to several blood cancer drugs, expediting the development process. Increased funding from governments and patient advocacy groups also supports research efforts, resulting in a pipeline of promising therapies. This regulatory support is critical in bringing new treatments to market faster, offering more effective options for patients with hematological malignancies.

What Drives the Growth of the Hematological Malignancies Market?

The growth in the hematological malignancies market is driven by the rising incidence of blood cancers, advancements in targeted and immunotherapies, and robust clinical trial activity. As cancer diagnoses increase globally, particularly in aging populations, there is an urgent demand for effective treatments. Targeted therapies and immunotherapies are improving treatment outcomes, particularly for patients unresponsive to traditional treatments. Regulatory support and active clinical trial pipelines are accelerating drug development, further expanding treatment options. Together, these factors are driving growth in the hematological malignancies market as it evolves to address unmet needs in oncology.

SCOPE OF STUDY:

The report analyzes the Hematological Malignancies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Condition (Leukemia, Lymphoma, Myeloma, Other Disease Conditions); Therapy (Chemotherapy, Immunotherapy, Targeted Therapy)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• AbbVie, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.